GBB
AI Biomedical R&D Company
Hong Kong
November 11, 2025
Great Bay Bio (referred to as "GBB") announced today the signing of a strategic cooperation agreement with Taihong Scientific Co., Ltd. (referred to as "Taihong Scientific"), a leading biotechnology service enterprise in Hong Kong, to establish a long-term, future-oriented partnership.This collaboration will fully integrate GBB's multiple AI-driven innovative technology platforms with Taihong Scientific's process development and biopharmaceutical commercialization capabilities. The two parties will engage in in-depth cooperation around key areas such as cell line development, protein purification, process scale-up, and technology transfer.This marks another new collaboration achieved by Great Bay Bio in Hong Kong, with multiple parties joining hands to create a more dynamic biotech innovation ecosystem in Hong Kong, providing a one-stop solution for the entire process from drug discovery to preclinical development for global biopharmaceutical companies.
GBB's AlfaCell, as the world's first commercially available targeted integration cell line development platform, boasts unique "dual-speed" and "high expression" advantages, completing the RCB production process in just 1.5 months compared to the traditional 6-month timeline, and rapidly predicting product quality within 1 month.It has disruptively accelerated the decision-making process for traditional process development and CMC development progress, achieving breakthrough advancements in expression levels across multiple product categories. For example, monoclonal antibodies reach up to 15g/L, bispecific antibodies up to 12g/L, and nanobodies up to 13g/L, making it the preferred tool for the efficient development of next-generation biologics such as bispecific antibodies, multispecific antibodies, fusion proteins, and ADCs.
Moreover, GBB has developed based on the AlfaCell platformAlfaexpress Transient Transfection Kit directly used for transient expression in CHO-K1 cell lines achieves expression levels as high as 300~700mg/L@day7,Capable of rapidly preparing protein samples, it solves the problem that traditional CHO-K1 cell transient expression can only rely on CHO-S or 293.Alfaexpress Transient Transfection Kit Achieves Seamless Transition from Transient to Stable Transfection in the Same Cell Line, Significantly Reducing Efficacy Differences Between Early Research and CMC Stages.
Taihong Science, as a laboratory service provider with extensive early preclinical development experience,With its own laboratory facilities in Hong Kong, it has the full-process service capabilities from cell line construction to protein purification and process development.A solid foundation supporting the development and production of biopharmaceuticals, with business operations spanning globally.
Through this collaboration, Great Bay Bio will authorize Taihong Science to use the industry-leading AlfaCell platform, Alfaexpress products, and related supporting technologies within its advanced experimental facilities, providing comprehensive technical services from cell line development and research cell banking to protein purification, quality control, and process development.
Our collaboration not only aligns with the strategic direction and vision of the Hong Kong Special Administrative Region government in promoting biotechnology innovation and technological development, but also leverages the technical expertise of Great Bay Bio.Taihong ScienceThe complementary strengths in operational excellence and market insight will jointly expand a more vibrant innovation ecosystem in Hong Kong. This collaboration will build an efficient platform for the transformation of Hong Kong's industry-university-research achievements, accelerating the transition of biopharmaceutical innovations from the lab to the market. In turn, this will strengthen Hong Kong’s position as a regional biotechnology hub, promoting high-quality and sustainable development of the local and regional biotech industries.
About Taihong Science
Taihong Scientific Co., Ltd. is a globally-oriented CDMO that has risen to prominence in Hong Kong. In addition to our 5,000-square-foot preclinical facility in Hong Kong and the planned cGMP expansion site in North America, what truly sets us apart is our talent. Our team possesses deep commercialization and CMC (chemistry, manufacturing, and control) practical experience, along with years of hands-on drug commercialization expertise. We adopt a "right-the-first-time" development philosophy, leveraging our team’s insights from clinical stages to ensure your drug development aligns with the appropriate clinical stage requirements and includes the critical data necessary for advancing clinical readiness.
Through our internal development platform and rapid process scaling capabilities, we can effectively eliminate the pain points in the CMC preparation process, accelerating your path to clinical and commercial value creation.
About Great Bay Bio
Great Bay Bio is a high-tech biotechnology company driven by cutting-edge technologies such as artificial intelligence, big data mining, and automation to advance drug development, with its headquarters located in the Hong Kong Science Park. Upholding the corporate vision of "making global bioprocess development simpler and more efficient," Great Bay Bio is committed to addressing various pain points in drug development, including long cycles, high costs, and low success rates, while striving to enhance human health and value as a long-term goal.
GBB's core team is composed of experts from various fields such as medicine, synthetic biology, and artificial intelligence both domestically and overseas. The company owns a 3,000-square-meter R&D laboratory base and a CMC platform, which has helped clients gain approval from the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA) for Investigational New Drug (IND) applications. Over the years since its establishment, GBB has filed nearly 100 patents for AI-driven drug development and successfully commercialized multiple AI technology platforms, establishing long-term cooperation with several leading enterprises in China and abroad. GBB has passed the ISO9001:2015 quality management system certification and was listed on the Forbes Asia-Pacific 100 Most Promising Companies in 2024.
END
Great Bay Bio and Taron Form Strategic Partnership to Advance HK Biopharmaceutical Innovation
Hong Kong
November 11, 2025
Today, Great Bay Bio (GBB) announced the signing of a strategic cooperation agreement with Taron Solutions Limited (Taron), a leading biotechnology service provider based in Hong Kong. The two companies will establish a long-term, forward-looking partnership integrating GBB’s multiple AI-driven innovation platforms with Taron’s process development and biotherapeutic commercialization capabilities. Through deep collaboration in key areas—including cell line development, protein purification, process scale-up, and technology transfer. This partnership marks another milestone for GBB in Hong Kong, as multiple parties join forces to foster a more vibrant biotech innovation ecosystem in the region—collectively providing global biopharmaceutical companies with comprehensive, end-to-end solutions spanning from drug discovery to preclinical development.
As the world’s first commercialized site-specific integration cell line development platform, AlfaCell combines the advantages of being “double fast” and high yield. It can generate the RCB in just 1.5 months—compared with 6 months traditionally—and predict product quality within 1 month, transforming conventional process development decisions and accelerating CMC timelines. AlfaCell also achieves breakthrough expression levels—up to 15 g/L for mAbs, 12 g/L for BsAbs, and 13 g/L for nanobodies—making it ideal for next-generation biotherapeutics such as BsAbs, multispecific antibodies, fusion proteins, and ADCs.
Building on the AlfaCell platform, GBB has developed the Alfaexpress transient expression kit, which produces 300–700 mg/L of protein by day 7 in CHO-K1 cells, overcoming the low-yield limitations of conventional CHO-S or 293 cell transient expression systems. It also allows seamless transition from transient to stable expression within the same cell line, minimizing efficacy gaps between early research and CMC development.
With extensive experience in early preclinical development, Taron operates its own facilities in Hong Kong and provides comprehensive, end-to-end services spanning cell line development, protein purification, process development, and more. Built on a strong foundation in biopharmaceutical development and manufacturing, Taron has expanded its business presence globally.
Through this collaboration, GBB and Taron will leverage the industry-leading AlfaCell platform, Alfaexpress kit, and related supporting technologies within Taron’s state-of-the-art facilities to provide technical services ranging from cell line development and research cell bank establishment to protein purification, quality control, and process development.
Our collaboration aligns with the Hong Kong government’s vision to advance biotech innovation. By combining GBB’s technological expertise with Taron’s operational excellence and market insight, the partnership accelerates biopharmaceutical innovation and reinforces Hong Kong as a regional biotech hub. Together, we are building an efficient platform that bridges laboratory discoveries to market applications, fostering a vibrant industry–academia ecosystem and driving sustainable growth in the local and regional biotechnology sector.
About Taron
Taron is a rising global CDMO based in Hong Kong. Beyond our infrastructure, including a 5,000 sq ft pre-clinical facility in Hong Kong and a planned cGMP facility expansion in North America, it's our people that distinguish us. Our team brings deep commercial and CMC (Chemistry, Manufacturing, and Controls) expertise, backed by decades of real-world drug commercialization experience. We follow a "right-the-first-time" approach, leveraging our team's clinical-stage insights to ensure your drug development is phase-appropriate with the data needed to advance toward clinical readiness. Through our internal development platform and rapid process scale-up capabilities, we take the pain out of CMC readiness.
About Great Bay Bio
Great Bay Bio (GBB), headquartered in HKSTP, is a biotech company that drives drug development using cutting-edge technologies such as AI, big data mining, and automation. GBB adheres to the corporate vision of "Global Bioprocessing Made Simpler and More Efficient," and aims to address the challenges of long timelines, high costs, and low success rates in drug development, with a long-term goal of enhancing human life, health, and value.
The core team of GBB comprises experts from medicine, synthetic biology, and artificial intelligence. The company operates a 3,000㎡ R&D laboratory and CMC platform, supporting customers in securing clinical trial approvals from China’s NMPA and the US FDA. GBB has secured nearly 100 patents related to AI-enabled drug development and successfully commercialized multiple AI technology platforms. The company has established long-term partnerships with leading domestic and international enterprises. GBB has passed the ISO 9001:2015 quality management system certification and been selected for Forbes Asia 100 to Watch 2024 List.
END